4SC to Present at Two Upcoming Investor Conferences
News Apr 17, 2012
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, will be presenting at two investor conferences this week.
Dr Ulrich Dauer, Chief Executive Officer of 4SC AG, will give a company presentation at the Future Leaders in the Biotech Industry conference, which will be held on 20 April 2012 in New York City, USA.
The presentation of 4SC will begin at 9.00am (ET).
Enno Spillner, Chief Financial Officer of 4SC AG, will give a company presentation at the 3rd FCF Family-to-Family Day, an investor conference exclusively for family offices and HNIs (High Net Worth Individuals) on 19 April 2012 in Munich.
The presentation of 4SC will begin at 3.15pm (CET).
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE
Chemists Have Synthesized New Isoquinoline DerivativesNews
Chemists have synthesized new isoquinoline derivatives. Due to their biological activity, these compounds may be applicable in new drugs, from antispasmodics to bactericidal agents. In addition, in the future they may show effectiveness in the treatment of Alzheimer's disease.READ MORE
Researchers Develop a Platform to Produce Brand-new AntibioticsNews
A team of scientists at the University of Bristol have generated a brand-new platform that will allow the production of desperately needed brand-new antibiotics.READ MORE